{
    "clinical_study": {
        "@rank": "25214", 
        "acronym": "LDN-IM", 
        "arm_group": {
            "arm_group_label": "Trial", 
            "arm_group_type": "Other"
        }, 
        "brief_summary": {
            "textblock": "We have found that low dose naltrexone (LDN) can substantially reduce pain associated with\n      fibromyalgia syndrome. We believe LDN may work via novel anti-inflammatory channels. The\n      purpose of this study is to determine if LDN lowers inflammatory markers in individuals with\n      fibromyalgia."
        }, 
        "brief_title": "Low Dose Naltrexone (LDN) Immune Monitoring", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Fibromyalgia", 
        "condition_browse": {
            "mesh_term": [
                "Fibromyalgia", 
                "Myofascial Pain Syndromes"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Females age 18-65\n\n          -  Meets criteria for 1990 ACR criteria for fibromyalgia\n\n          -  Able to receive venous blood draw twice a week for 16 weeks\n\n          -  Sufficient symptom variability during baseline report\n\n          -  Patient completes daily report during 2 week baseline period at least 80% completion\n             rate.\n\n        Exclusion Criteria:\n\n          -  Opioid use\n\n          -  Significant psychological comorbidity that in the discretion of the investigator\n             compromises study integrity\n\n          -  Location prohibits travel to Stanford\n\n          -  Blood or clotting disorder\n\n          -  Rheumatologic or autoimmune disease\n\n          -  Acute infection\n\n          -  Baseline blood ESR >60, CRP greater than 3.0mg/L, positive rheumatoid factor, or\n             positive ANA\n\n          -  Use of blood thinning medication\n\n          -  Pregnant or currently planning to become pregnant\n\n          -  Current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory\n             medication as part of regular medication regimen.\n\n          -  Known allergy to Naltrexone or Naloxone\n\n          -  Currently participating in another treatment-based research study\n\n          -  Self-reported inability to refrain from alcohol for the duration of the study period"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 1, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02107014", 
            "org_study_id": "29911"
        }, 
        "intervention": [
            {
                "arm_group_label": "Trial", 
                "intervention_name": "Low Dose Naltrexone", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Trial", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Naltrexone"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "contact": {
                "email": "youngerlab@stanford.edu", 
                "last_name": "Luke Parkitny, PhD", 
                "phone": "650-497-7671"
            }, 
            "facility": {
                "address": {
                    "city": "Palo Alto", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94304"
                }, 
                "name": "Stanford University School of Medicine"
            }, 
            "investigator": {
                "last_name": "Jarred Younger, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Low Dose Naltrexone (LDN) Immune Monitoring", 
        "overall_contact": {
            "email": "youngerlab@stanford.edu", 
            "last_name": "Jarred Younger, PhD", 
            "phone": "650-721-1988"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change in pain from placebo period to end of drug period correlated with change in immune markers from placebo to end of drug period", 
            "measure": "Change in average daily pain (0-100 Visual Analogue Scale) correlated with change in immune markers", 
            "safety_issue": "No", 
            "time_frame": "End of placebo compared to end of drug period. Total comparison period is 12 weeks."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02107014"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Stanford University", 
            "investigator_full_name": "Jarred Younger, PhD", 
            "investigator_title": "Assistant Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Stanford University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Stanford University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}